Goodwin Biotechnology, Inc. has recently expanded its Bioconjugation capabilities by adding a dedicated suite for developing and manufacturing cytotoxic Antibody Drug Conjugates (ADCs) up to Safebridge level 4/5.

“For over 15 years, Goodwin Biotechnology has been one of the pioneers in providing development and GMP manufacturing of a broad portfolio of  ADC projects, including cytotoxic ADCs, Radio-Immunoconjugates, Antibody-Peptide Conjugates, Antibody-Dye Conjugates, PEGylated proteins, other bioconjugates, and even Biobetters,” said Muctarr Sesay, Ph.D., chief scientific officer and vice president of Bioconjugation Development at Goodwin Biotechnology. “Our experience in Bioconjugation has resulted in several patents and publications, as well as proprietary processes that enable us to help our clients overcome some significant challenges in developing their next generation of ADCs.  Given the increasing interest in conjugating highly cytotoxic products (e.g., anti-cancer drugs) to enhance the efficacy of ADCs, we have added a dedicated ISO-7 Cytotoxic Process facility for Proof of Concept, development, Tox and cGMP manufacturing to address unmet clinical needs.”